Key Points Oral SKNY-1 significantly reduced body weight and fat mass compared with vehicle-treated controls in an exploratory mouse study. Weight reduction occurred without a…
Key Points Humacyte received U.S. Patent No. 12,742,144, covering aspects of manufacturing, sterilization, storage and shipping for Symvess and other bioengineered human tissues. The patent…
October 27, 2026
Vanda Reports Positive Phase 3 Results for NEREUS in Preventing GLP-1-Related Vomiting
Key Points Vanda’s NEREUS reduced the proportion of participants who vomited after semaglutide from 58.5% with placebo to 43.0%. The trial met its primary endpoint,…
Key Points Cumberland Pharmaceuticals plans to seek FDA approval for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy, or DMD. The FDA granted rolling…
October 22, 2026
Verrica Unlocks Full $27.5 Million Credit Facility to Support YCANTH Growth and Warts Trials
Key Points Verrica met revenue, growth and operational milestones that unlocked an additional $15 million in borrowing capacity. The full $27.5 million facility is now…
October 22, 2026
Sagimet Doses First Patient in Phase 3 U.S. Acne Trial, Targets Results in Late 2027
Key Points Sagimet Biosciences has dosed the first patient in AURORA, its pivotal U.S. Phase 3 trial of denifanstat for moderate to severe acne. The…
Key Points Jaguar Health reported that an infant with a rare genetic form of intestinal failure needed approximately 15% less daily parenteral support after several…
October 21, 2026
Invivyd Reports Encouraging Lab Results for Measles Antibody, Targets Clinical Development in 2027
Key Points Invivyd presented preclinical findings for VMS063, an experimental antibody being developed to treat and prevent measles. Laboratory testing showed potent antiviral activity against…
Silence Therapeutics (NASDAQ: SLN) jumped about 125% to roughly $19.57 by Mid-day, after agreeing to an all-cash acquisition by Merck KGaA at $20.00 per ADS….
Key Points NRx Pharmaceuticals completed three commercial-scale validation lots of its preservative-free ketamine. Two-year room-temperature testing showed no deterioration in purity, potency or sterility, according…
Key Points Actinium Pharmaceuticals appointed Sean Maenpaa as Senior Vice President of Business Development, effective October 12, 2026. He brings more than 20 years of…
October 16, 2026
QRX003 Reaches Eight Significant Regulatory Designations as Quoin Adds EU Orphan Status in Peeling Skin Syndrome
Until this year, no company had ever filed an IND with the FDA for Peeling Skin Syndrome (PSS). Now the disease has a clinical trial…